Medtronic plc, a global leader in medical technology, on Tuesday launched its next-generation Avalus Ultra™ Bioprosthesis surgical aortic heart valve in India, aiming to enhance cardiac care for patients nationwide. Building on the decade-long clinical experience of the Avalus™ platform, the Avalus Ultra valve is designed for ease of implantation, durability, and reliable performance, including support for future transcatheter aortic valve-in-surgical aortic valve (TAV-in-SAV) procedures.
The low-profile valve accommodates diverse patient anatomies, featuring a flexible sewing cuff for secure placement with minimal paravalvular leak rates. Platinum-iridium coils and tantalum badges improve fluoroscopic visibility during reinterventions, ensuring accurate positioning. The device leverages AOA tissue treatment technology, proven across half a million patients over 30 years, promising excellent long-term outcomes.
Prateek Tiwari, Senior Director, Neuroscience and Specialty Therapies at Medtronic India, said, “The Avalus Ultra valve simplifies implantation and enhances reliability, supporting clinicians in delivering consistent, tailored outcomes while advancing patient lifetime management.” In Kolkata, cardiologists and hospitals have welcomed the launch, citing the city’s growing cardiac patient base and demand for advanced valve therapies. Clinics report increased inquiries for valve replacement procedures, reflecting rising awareness and confidence in innovative solutions like Avalus Ultra. With backing from the PERIGON Pivotal Trial, which demonstrated 99% freedom from structural valve deterioration over seven years, Medtronic continues to reinforce its commitment to long-term cardiac health in India.